BioAngels

Investors meet BioEntrepreneurs

BioAngels is an exclusive matchmaking concept for private investors such as business angels, wealthy individuals, family offices and conventional venture capital investors determined to invest in life sciences & health technology.

Matchmaking

We introduce private investors to selected, innovative start-up projects at an early stage. 

BioEntrepreneurs planning a spin-off or start-up in search of investors can apply with us to present their business idea to our BioAngels. The presenting teams will be prepared by us to submit all relevant information needed for deciding on an investment in an appropriate manner.

Focus on health care sector

Our circle of investors is interested in participating in the following areas:

  •     Innovative drug development
  •     New diagnosis procedures
  •     Big data & digital health
  •     New drug technologies and approaches to regenerative drugs
  •     Innovative platform technologies and services

     

    „On the BioAngels Pitch Day, it is easy to talk to the teams. That would be harder on large investment conferences. I also greatly appreciate the exchange with the other investors.“
    Dr. Hubert Birner, TVM Capital

     

    „The preparation by the team of BioM was very good and intensive. The criticizing feedback has helped us tailor our presentation to the demands of investors.“
    Dr. Kathrin Ladetzki-Baehs, adivo.


More about this topic

Multi-million euro seed funding for deepc

Mu­nich-based MedTech star­tup deepc has suc­cess­fully closed a seed fin­an­cing round worth a mid-seven-fig­ure sum. In ad­di­tion to…

MorphoSys and m4 Award winner Cherry Biolabs Announce Hemibody Technology License Agreement

MorphoSys and the Würzburg-based start-up Cherry Bi­olabs signed a li­cense agree­ment on the use of Cherry Bi­olabs' hemibody tech­no­logy…

CatalYm raises €50 million for treatment of checkpoint inhibitor refractory tumors

CatalYm GmbH, based in Martin­sreid near Mu­nich, has con­cluded a Ser­ies B fin­an­cing of 50 mil­lion euros. The bio­phar­ma­ceut­ic­al…

Dr. Petra Burgstaller
Dr. Petra Burgstaller

Head of inQlab


Christina Enke-Stolle
Christina Enke-Stolle

Head of inQlab